Elan Sues Over Biogen Objection To $1B J&J Deal

Law360, New York (August 6, 2009, 5:39 PM EDT) -- Elan Corp. PLC went on the offensive Thursday against Biogen Idec Inc., its partner in developing the multiple sclerosis treatment Tysabri, to secure a court order that a $1 billion acquisition deal with a Johnson & Johnson affiliate does not violate its collaboration agreement with Biogen Idec.

Elan Pharma International Ltd. filed suit in the U.S. District Court for the Southern District of New York, seeking a declaration that its parent company can go ahead with the transaction, despite a letter Biogen Idec sent to the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.